Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer

Post Traumatic Stress Disorder Clinical Trial

Official title:

Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure With a Cognitive Enhancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01352637
• Other study ID #: 1005011047
• Status: Completed
• Phase: Phase 3
• Start date: May 2011
• Est. completion date: September 2018

Study information

• Verified date: June 2019
• Source: Weill Medical College of Cornell University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the differences between four active treatment conditions for combat-related Post Traumatic Stress Disorder (PTSD): virtual reality exposure therapy (VRE) or prolonged imaginal exposure therapy (PE), both with DCS or placebo, as well as to examine predictors for PTSD and response to treatment in active duty military personnel, veterans, and civilians who served in Iraq and Afghanistan.

Description:

Post Traumatic Stress Disorder (PTSD) is an anxiety disorder that can develop following exposure to traumatic events and includes symptoms of re-experiencing the trauma, such as through nightmares and flashbacks, avoidance and numbing, and physical hyperarousal. PTSD has been estimated to affect 10-20% of returning Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) veterans. The most effective intervention found for PTSD is exposure therapy, which can be delivered in different formats, e. g. via virtual reality (VR) and as imaginal exposure. The goal of this study is to test the difference between 4 study conditions: virtual reality exposure therapy (VRE) or prolonged imaginal exposure therapy (PE), both combined with an antibiotic drug, DCS (active pill vs. placebo). D-Cycloserine (DCS), a drug that has been FDA approved for over 20 years, has been hypothesized to enhance the therapeutic effects of exposure therapy.). A secondary purpose of this study is to examine predictors for PTSD and response to PTSD intervention in active duty military personnel, veterans, and civilians who served in Iraq/Afghanistan. Psychophysiological factors (e.g. heart rate, blood pressure) and/or a genetic polymorphism (BDNF Val66Met) obtained from a saliva sample will be examined.

The two primary co-aims are

1. to examine the effects of DCS versus placebo (PLA) augmentation of exposure therapy on PTSD symptoms, and

2. to examine the relative efficacy of virtual reality enhanced exposure therapy (VRE) and exposure therapy (PE) on PTSD symptoms.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 192
• Est. completion date: September 2018
• Est. primary completion date: September 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of OEF-OIF (Operations Enduring Freedom or Iraqi Freedom) Combat Related PTSD;

2. Female participants of childbearing potential must agree to use an effective method of birth control (i.e., oral contraceptive, Norplant, diaphragm, condom, or spermicide) during the course of the study, or to remain abstinent from sex, to ensure they do not become pregnant during the course of the study;

3. Ability to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments;

4. Participants must be literate in English;

5. Patients must be medically healthy and willing to take the study drug;

6. VRE stimuli available must be consistent with subject's trauma.

Exclusion Criteria:

1. Lifetime or current diagnosis of schizophrenia or other psychotic disorder, bipolar disorder;

2. Participation in a clinical trial during the previous 3 months;

3. Current evidence or history of significant unstable medical illness or organic brain impairment, including stroke, CNS tumor, demyelinating disease, cardiac, pulmonary, gastrointestinal, renal or hepatic impairment;

4. Patients who in the investigator's judgment pose a current suicidal or homicidal risk;

5. Alcohol, medication, or illegal substance dependence within the past 90 days;

6. Treatment with any other concomitant medication with primarily CNS activity, or treatment with any medication that the PI judges not acceptable for this study;

7. history of seizures;

8. Pregnancy or lactation.

Related Conditions & MeSH terms

• Post Traumatic Stress Disorder
• Stress Disorders, Post-Traumatic
• Stress Disorders, Traumatic

Intervention

Drug:
• DCS (D-Cycloserine ) + Prolonged Imaginal Exposure
50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
• DCS (D-Cycloserine ) + Virtual Reality Exposure
50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure
• Placebo + Prolonged Imaginal Exposure
Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
• Placebo (sugar pill) + Virtual Reality Exposure
Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure

Locations

Country	Name	City	State
United States	Emory University	Atlanta	Georgia
United States	Walter Reed Army Medical Center/National Intrepid Center of Excellence (NICoE)	Bethesda	Maryland
United States	VA Long Beach Healthcare System	Long Beach	California
United States	University of Southern California	Los Angeles	California
United States	Weill Cornell Medical College	New York	New York

Sponsors (6)

Lead Sponsor	Collaborator
Weill Medical College of Cornell University	Emory University, National Intrepid Center of Excellence, United States Department of Defense, University of Southern California, VA Long Beach Healthcare System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CAPS-IV at the End of Treatment	Clinician Administered PTSD Scale (CAPS) for the DSM-IV [34]. The CAPS-IV is a structured clinical interview designed to assess the 17 DSM-IV PTSD symptoms. CAPS-IV provides categorical ratings of diagnostic status as well as a quantitative index of symptom severity. The CAPS total severity score is based on response to the 17 items that assess the frequency and intensity of current PTSD symptoms. Symptom severity is assessed separately for past month and past week time frames.; CAPS-IV range is 0-136, higher scores mean a worse outcome.	after weekly treatment session 9 (at posttreatment assessment)

External Links

•   Link